TOCSINGROUP

Industries

Medical Devices & Supplies

Device, instrument, prosthetic, and medical supply manufacturers. Clearance rules, coverage and payment, tariff lines, and procurement preferences decide which products reach patients.

Measures whose provisions reach this industry directly, verified against the bill text. Measures written for this industry lead the list, then measures that plainly change how it operates; within each, the likeliest to become law come first. Measures that have become law or failed are removed.

Measures that reach Medical Devices & Supplies directly

HR 10787 US House Last action
October 9, 2026 BenefitLong shot

Access to Medical Supplies Act

Gregory F. Murphy (Republican) · Sponsor of record · Official record ↗

What it does
The bill would remove urological and ostomy supplies from Medicare's competitive bidding program for five years, from January 1, 2028 through January 1, 2033, so those supplies would be paid for outside the bidding process. It would also require the Health and Human Services Secretary to set up a technical expert panel with patients, clinicians, and supply experts to study how such supplies could be included in bidding, run a small demonstration project in up to 3 states for 12 months to test their inclusion, bar contract suppliers from pressuring patients to switch supply brands, and guarantee patients a right to get their same or comparable supplies from another supplier if they cannot access them. This bill benefits manufacturers of urological and ostomy supplies by keeping their products outside Medicare's competitive bidding program for five years and guarantees they join a required technical expert panel that shapes future bidding policy, while distributors and suppliers keep existing payment rates and customers.
Where it stands
HR10787, the Access to Medical Supplies Act, was referred on October 9, 2026 to the House Committee on Energy and Commerce and, in addition, to the House Committee on Ways and Means, for a period to be subsequently determined by the Speaker. The bill is in the ordinary committee stage: no hearing or markup has been noticed in our calendar data, and each referred committee chair is a gatekeeper for the provisions within that panel's jurisdiction.
S 5513 US Senate Last action
September 24, 2026 MixedLong shot

Domestic Manufacturing Revitalization Act of 2026

Bill Cassidy (Republican) · Sponsor of record · Official record ↗

What it does
The bill would create a Medicare pilot program requiring hospitals whose Medicare payments over the prior five years exceeded the hospital average to buy at least 40 percent of their personal protective equipment and medical consumables from domestic producers, with Medicare payments to participating hospitals that fall short cut by 2 percent for one missed year rising to 8 percent after seven missed years, while participating hospitals are reimbursed for their domestic purchases from tariff revenue the bill collects. It would also impose a 300 percent tariff on a list of imported medical supplies, phased in from 10 percent of the increase after 180 days to the full amount after 5 years, and give tax credits to US manufacturers of 25 cents per N95 respirator, 10 cents per surgical mask, and smaller or larger amounts for other items such as gloves, gowns, and ventilators, plus a 20 percent credit for building PPE manufacturing facilities. This bill directly benefits domestic manufacturers of masks, gloves, gowns, and other medical supplies with per-unit tax credits, a 20 percent credit for building PPE plants, a 300 percent tariff on competing imports, and guaranteed hospital purchases, while requiring annual sworn domestic-content attestations.
Where it stands
S. 5513 was read twice and referred to the Senate Committee on Finance on September 24, 2026, so it sits at the committee stage, where most Senate bills stop. Nothing in the record shows any further action, and no committee meeting appears on the calendar.
S 5239 US Senate Last action
August 4, 2026 MixedLong shot

American Glove Act of 2026

Bernie Moreno (Republican) · Sponsor of record · Official record ↗

What it does
The bill would require federal agencies including Homeland Security, Health and Human Services, Veterans Affairs, and Defense to buy non-surgical nitrile gloves only from US-based, US-majority-owned manufacturers that make the gloves domestically, and it would require any contract vehicle used for these purchases, including ones run through the AbilityOne Program, to include supplier agreements of at least two years with binding minimum purchase commitments to those manufacturers. Agencies would have to certify compliance and could not swap manufacturers without a written contract modification, with resale, relabeling, or warehousing of foreign-made gloves not counting as domestic manufacturing. This bill requires federal agencies to buy nitrile gloves only from qualified domestic manufacturers, giving US-owned medical glove makers guaranteed long-term government contracts while disqualifying foreign-owned or foreign-controlled manufacturers from selling to the government.
Where it stands
S5239, the American Glove Act of 2026, was read twice and referred to the Committee on Homeland Security and Governmental Affairs on August 4, 2026. It now sits at the committee stage, the most common early choke point, with no markup or hearing scheduled in our calendar data.
HR 9972 US House Last action
July 27, 2026 BurdenLong shot

American Patients First Act of 2026

Pete Sessions (Republican) · Sponsor of record · Official record ↗

What it does
The bill sets a fixed Medicare payment rate of $457 per square centimeter for skin substitute products from 2027 to 2030 and requires that these products be manufactured and sourced entirely within the United States. It also imposes strict prior authorization rules, certification requirements for providers, and limits on the amount of product paid for per wound to reduce fraud and overuse. This bill directly regulates medical supply manufacturers by guaranteeing a fixed Medicare rate of $457 per square centimeter for skin substitute products from 2027 through 2030, but only for products fully manufactured, sourced, and distributed in the United States with annual attestation filings.
Where it stands
The American Patients First Act of 2026 was referred on July 27, 2026, to the House Committee on Energy and Commerce and the House Committee on Ways and Means. This multiple referral places the bill under the jurisdiction of both panels for consideration of provisions within their respective areas, with the Speaker determining the time period for each.
HR 9791 US House Last action
July 20, 2026 MixedLong shot

NO FEES Act of 2026

Scott Perry (Republican) · Sponsor of record · Official record ↗

What it does
The bill defines a small business for device fee waivers as an entity with fewer than 20 full-time equivalent employees and prohibits considering past payment history when granting these waivers. It also requires foreign-owned establishments to pay an annual registration fee equal to eight times the standard amount. This bill gives medical device manufacturers with fewer than 20 employees waivers on annual registration fees plus a five-year exemption period, while charging foreign-owned device makers eight times the standard registration fee and barring them from waivers.
Where it stands
HR 9791 was referred to the House Committee on Energy and Commerce on July 20, 2026, placing it in the committee stage where the chair controls whether a hearing or markup is scheduled. The measure has not yet received a markup or report.
S 4994 US Senate Last action
July 15, 2026 BenefitLong shot

ONSHORE Manufacturing Act

Marsha Blackburn (Republican) · Sponsor of record · Official record ↗

What it does
This proposal would create three new tax credits for companies that manufacture essential medical supplies, drugs, and devices within the United States, including credits for production income, advanced equipment, and environmental compliance costs. These tax benefits would apply to taxable years beginning after December 31, 2026, for production credits and immediately upon enactment for equipment and compliance credits, while requiring federal agencies to report annually on their impact on supply chains and domestic procurement. This bill gives tax credits to U.S. medical device and supply manufacturers, including a credit on domestic production income, credits for advanced manufacturing equipment, and credits for environmental compliance costs, lowering their federal tax burden.
Where it stands
S4994 was read twice and referred to the Committee on Finance on July 15, 2026, and no future meetings are scheduled in the current calendar data.
HR 9635 US House Last action
July 9, 2026 BenefitLong shot

Getting Innovations to Patients During Shutdowns Act

Kevin Mullin (Democrat) · Sponsor of record · Official record ↗

What it does
The bill allows the FDA to accept complete drug and device applications during a government shutdown even if the required fees have not yet been paid. It extends the deadline for paying these fees until seven days after the shutdown ends. This bill lets medical device and supply manufacturers submit complete device applications to the FDA during a government shutdown without paying fees upfront, extending the payment deadline to seven days after the shutdown ends so reviews stay on schedule.
Where it stands
HR 9635 was referred to the House Committee on Energy and Commerce on July 9, 2026, and has not yet received committee action. The committee chair controls whether a hearing or markup is noticed, and no meetings are currently scheduled.
S 4939 US Senate Last action
June 24, 2026 BurdenLong shot

Countering CCP Act

Tom Cotton (Republican) · Sponsor of record · Official record ↗

What it does
The bill requires the Secretary of Health and Human Services to review medical devices made in China for cybersecurity risks and order their removal from the market if they pose a threat or if manufacturers fail to provide required security information. It also mandates a report on the cybersecurity preparedness of the domestic medical device industry and the market share of Chinese manufacturers. This bill directs manufacturers of medical devices made in China to provide security information to HHS and, if a device poses a cybersecurity risk or information is withheld, to cease distribution and notify health professionals, retailers, and users, with exemptions when removal would endanger patients.
Where it stands
S4939 was read twice and referred to the Committee on Health, Education, Labor, and Pensions on June 24, 2026, placing it in the committee stage where the chair controls scheduling for a hearing or markup.
S 4519 US Senate Last action
May 13, 2026 BenefitLong shot

Medical Device Electronic Labeling Act

Jim Banks (Republican) · Sponsor of record · Official record ↗

What it does
The bill would amend federal drug law so that manufacturers of medical devices, including in vitro diagnostic devices, could satisfy required labeling by making it available only electronically, as long as users can easily access it and get a free paper copy on request. It would also let the Food and Drug Administration order additional labeling requirements or exceptions where needed for devices used without provider supervision or where electronic-only labeling would not assure safety, and would require the agency to seek public comment within two years on improving electronic labeling for devices used in health care facilities and by professionals. This bill lets medical device and in vitro diagnostic manufacturers satisfy FDA labeling requirements entirely electronically, cutting printing costs, as long as they give users easy access and free paper copies on request.
Where it stands
S4519 was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on May 13, 2026. It now sits in committee, where the chair decides whether anything happens at all, and no hearing or markup is currently scheduled in the available calendar data.
S 4440 US Senate Last action
April 29, 2026 BenefitLong shot

Clinical Trial Modernization Act

Tim Scott (Republican) · Sponsor of record · Official record ↗

What it does
This bill allows drug and device manufacturers to pay for clinical trial participants' travel, meals, and insurance cost-sharing without violating federal anti-kickback or false claims laws. It also excludes up to $2,000 in annual trial-related payments from participants' taxable income and authorizes grants to recruit underrepresented populations. This bill directly benefits medical device and supply manufacturers by letting them pay clinical trial participants' travel, meals, and insurance cost-sharing without violating federal anti-kickback or false claims laws, reducing their liability risk.
Where it stands
S4440 was read twice and referred to the Senate Committee on Finance on April 29, 2026, where it remains pending with no scheduled hearings or markups. The companion House bill HR3521 is similarly stalled in committee, having last been referred to the Committee on Energy and Commerce and the Committee on Ways and Means on May 20, 2025.
HR 5343 US House Last action
September 17, 2025 BenefitLong shot

Ensuring Patient Access to Critical Breakthrough Products Act

Blake D. Moore (Republican) · Sponsor of record · Official record ↗

What it does
The bill would require Medicare to cover FDA-designated breakthrough devices for a 4-year transitional coverage period beginning on designation, with the Health and Human Services Secretary accepting designation applications starting 18 months after enactment, deciding each within 6 months, and ensuring a final national coverage decision before the transition period ends for requests submitted at least 9 months beforehand (12 months for certain requests). It also bars Medicare payment when such devices are furnished more often than their FDA-approved labeling allows or by providers the Secretary flags for aberrant billing, and it appropriates $10 million per year for fiscal years 2026 through 2031 to the Centers for Medicare & Medicaid Services to run the new process. This bill gives medical device makers whose products win breakthrough designation four years of Medicare coverage and a guaranteed national coverage decision, opening Medicare payment for those devices.
Where it stands
The House referred HR 5343 to the Committees on Ways and Means and on Energy and Commerce on September 15, 2025, and the Ways and Means Committee held a markup on September 17, 2025, voting 37 to 3 to order the bill reported in the nature of a substitute. No written report has been filed and no calendar placement appears on the record.
HR 6852 US House Last action
December 18, 2025 BenefitLong shot

Advanced Wound Care and Regenerative Medicine Access and Reform Act

Gabe Evans (Republican) · Sponsor of record · Official record ↗

What it does
This act establishes a new volume-weighted average payment rate for Medicare coverage of skin substitute products starting in 2026 and mandates equivalent reimbursement regardless of the site of care. It also directs the Secretary of Health and Human Services to review and potentially streamline approval processes for human tissue products while imposing fraud prevention measures on high-volume providers. This bill gives skin substitute manufacturers a new volume-weighted Medicare payment rate starting in 2026 with equal payment regardless of care setting, while streamlining approval for tissue products and adding fraud reviews on high-volume providers.
Where it stands
HR 6852 was referred on December 18, 2025, to the House Committee on Energy and Commerce and the House Committee on Ways and Means, with the Speaker yet to determine the specific time limits for consideration.
HR 6549 US House Last action
May 20, 2026 BurdenLong shot

VA Contracting and Procurement Act

Jack Bergman (Republican) · Sponsor of record · Official record ↗

What it does
The bill would cap at $50 million any VA contract or agreement for contracts, personal services, community care, shared health-care resources, benefit administration, and veteran-owned small business contracting unless Congress specifically authorizes the funds, with exceptions during wars, War Powers situations, national emergencies, major disasters, and public health emergencies, and with a congressional notification and disapproval process for large educational benefits agreements. It would also require that items bought for VA emergency stockpiles comply with domestic preference laws favoring American-made goods unless the Secretary finds compliance would threaten veterans' health or safety, and it would overhaul prosthetic and surgical implant purchasing by requiring a catalog with a streamlined electronic process for manufacturers to propose updates and by mandating all surgical implants be bought through a single firm-fixed-price purchase order. This bill requires VA to buy health-care items for emergency caches from domestic manufacturers and to purchase all surgical implants through standardized firm-fixed price catalog orders, changing procurement rules for device and supply makers who sell to the VA.
Where it stands
H.R. 6549 was referred on December 10, 2025 to the House Committee on Veterans' Affairs and, in addition, to the House Committee on Rules, each for provisions within its jurisdiction. The Veterans' Affairs Committee has taken the bill up at the full committee level, holding hearings on March 18, 2026 and May 20, 2026, but no markup is scheduled in our calendar data, so the bill remains stalled in committee.
HR 6594 US House Last action
December 10, 2025 BurdenLong shot

Medical Device Recall Improvement Act of 2025

Janice D. Schakowsky (Democrat) · Sponsor of record · Official record ↗

What it does
The bill requires medical device manufacturers and importers to submit recall notifications through a standardized electronic format and mandates that they notify patients treated with recalled implants or life-sustaining devices. It also authorizes $14.4 million in total appropriations from fiscal year 2026 through 2030 to fund the implementation of these electronic notification systems and personnel. This bill requires medical device manufacturers and importers to submit recall notifications through a standardized electronic format, directly notify patients treated with recalled implants or life-sustaining devices, and face liability for failing to do so, with $14.4 million appropriated for implementation.
Where it stands
HR 6594 was referred to the House Committee on Energy and Commerce on December 10, 2025, and no upcoming meetings are scheduled in the current calendar data. The companion measure S 3421 was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on the same date.
S 3421 US Senate Last action
December 10, 2025 BurdenLong shot

Medical Device Recall Improvement Act of 2025

Richard J. Durbin (Democrat) · Sponsor of record · Official record ↗

What it does
The bill requires medical device manufacturers and importers to submit recall notifications to the government and healthcare providers using a standardized electronic format with specific mandatory data elements. It also mandates that manufacturers instruct healthcare providers to notify patients directly about recalls involving implanted, life-sustaining, life-supporting, or pediatric devices. This bill requires medical device manufacturers and importers to submit recall notices to the government, healthcare providers, and device user facilities in a standardized electronic format, and to notify patients about recalls of implanted, life-sustaining, life-supporting, or pediatric devices, with failure to comply treated as a prohibited act.
Where it stands
The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions on December 10, 2025. It currently sits in committee where the chair controls whether a hearing or markup is scheduled.
S 3325 US Senate Last action
December 3, 2025 MixedLong shot

Expanding Access to Affordable Drugs and Medical Devices Act

Jacky Rosen (Democrat) · Sponsor of record · Official record ↗

What it does
The bill allows the Treasury Secretary to designate certain drug and medical device manufacturers as tax-exempt organizations if they primarily aim to make eligible products affordable and meet specific organizational independence standards. Designated entities must agree to provide priority access to their products for the national stockpile during emergencies at a capped price, and they face penalties if they accept excessive funding from for-profit companies. This bill lets nonprofit drug and medical device manufacturers gain tax-exempt status if they meet affordability and transparency rules, in exchange for selling to the national stockpile at capped prices during emergencies, while for-profit device makers face new tax-advantaged competition.
Where it stands
S3325 is referred to the Senate Committee on Finance, where the chair controls whether a hearing or markup occurs. No upcoming meetings are scheduled, leaving the measure in a quiet holding pattern typical for most referred legislation.
HR 6197 US House Last action
November 20, 2025 BenefitLong shot

Health Tech Investment Act

John Joyce (Republican) · Sponsor of record · Official record ↗

What it does
This act requires Medicare to pay for certain algorithm-based healthcare services based on costs submitted by manufacturers and prevents their removal from a special payment category for at least five years. It also codifies a policy allowing hospitals to receive payment for software used as a service in outpatient settings. This bill requires Medicare to pay algorithm-based healthcare services at rates based on costs manufacturers submit, letting software and device makers secure stable reimbursement in a new outpatient payment category for at least five years.
Where it stands
The Health Tech Investment Act was referred on November 20, 2025, to the House Committee on Energy and Commerce and the House Committee on Ways and Means. This multiple referral requires each committee to consider provisions within its jurisdiction, though the record does not designate a primary panel.
HR 6117 US House Last action
November 18, 2025 BurdenLong shot

Patient Device Data Access Act of 2025

Mikie Sherrill (Democrat) · Sponsor of record · Official record ↗

What it does
This bill authorizes the Secretary of Health and Human Services to mandate that manufacturers of certain implanted or remote-monitoring medical devices disclose patient-specific data to patients upon request. The authorized regulations may also require manufacturers to publish information about data types and access methods on their websites and to notify patients of device recalls or updates. This bill lets HHS require manufacturers of implanted and remote-monitoring medical devices to give patients their device data, publish covered-device notices on their websites, and alert patients to recalls and updates, with penalties for noncompliance.
Where it stands
HR 6117 was referred to the House Committee on Energy and Commerce on November 18, 2025. The measure is currently at the committee stage, where the chair determines if a hearing or markup is scheduled.
S 3081 US Senate Last action
October 30, 2025 MixedLong shot

Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

Ted Cruz (Republican) · Sponsor of record · Official record ↗

What it does
This bill would allow the FDA to grant marketing approval to drugs, biological products, and devices already authorized in certain foreign countries or the United Kingdom within 30 days of a request. It establishes a streamlined pathway for these products to enter the US market if they meet specific safety and effectiveness criteria and address a public health need. This bill lets device and medical supply makers win FDA marketing approval within 30 days for products already authorized in listed foreign countries, provided they submit safety information and translations and pay the application fee.
Where it stands
S3081 was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on October 30, 2025, and no calendar placement is in the record. The bill currently resides in committee, where the chair controls whether any hearing or markup occurs.
HR 5605 US House Last action
September 26, 2025 BurdenLong shot

Medical Device Nonvisual Accessibility Act of 2025

Janice D. Schakowsky (Democrat) · Sponsor of record · Official record ↗

What it does
The bill would require manufacturers of certain home-use medical devices to ensure their digital interfaces are accessible to blind and low-vision individuals. It would also direct the government to issue regulations establishing these standards and provide training to manufacturers on compliance. This bill requires manufacturers of Class II and III home-use medical devices with digital interfaces, like thermometers and inhalers, to make those interfaces usable by blind and low-vision people or their devices will be deemed adulterated.
Where it stands
HR 5605 was referred to the House Committee on Energy and Commerce on September 26, 2025, with no upcoming meetings scheduled in the calendar data. The prior version HR 1328 remains not reported and last saw action in March 2023.
S 2710 US Senate Last action
September 4, 2025 BurdenLong shot

Open Payments Expansion Act

Chuck Grassley (Republican) · Sponsor of record · Official record ↗

What it does
The bill would require pharmaceutical manufacturers, device manufacturers, and group purchasing organizations to publicly report the names and dollar amounts of any direct or indirect payments they make to patient advocacy organizations. These disclosures would be submitted annually to the Secretary of Health and Human Services starting in March 2027. This bill requires device manufacturers and medical supply makers that qualify as applicable manufacturers, along with group purchasing organizations, to report annually to HHS the names and dollar amounts of payments they make to patient advocacy organizations.
Where it stands
S2710 was read twice and referred to the Committee on Finance on September 4, 2025, where it remains stalled with no scheduled meetings, hearings, or markups.
S 1717 US Senate Last action
May 12, 2025 BenefitLong shot

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Todd Young (Republican) · Sponsor of record · Official record ↗

What it does
This bill requires Medicare to cover designated breakthrough medical devices for a four-year period while their coverage is being finalized, unless they pose an undue risk of harm. It also appropriates $60 million from fiscal years 2026 through 2031 to administer this new designation and coverage process. This bill gives medical device manufacturers whose products are FDA-designated breakthrough devices a guaranteed four-year window of Medicare coverage while a permanent national coverage decision is finalized, with $60 million in funding to run the process.
Where it stands
The bill was read twice and referred to the Senate Committee on Finance on May 12, 2025, and remains stalled with no upcoming meetings scheduled. The companion measure HR5343 was ordered to be reported by a committee in the House on September 17, 2025, but has not passed a chamber.
HR 5039 US House Last action
August 26, 2025 BurdenLong shot

Wheelchair Right to Repair Act

Maxwell Frost (Democrat) · Sponsor of record · Official record ↗

What it does
This proposal would allow people to bypass digital security locks on electric wheelchairs and robotic walking devices to repair them, and it would require manufacturers to make repair parts, manuals, and software available to independent technicians and owners on fair terms. Manufacturers must also provide clear notices about these repair rights to customers and establish a public process for requesting repair tools within 90 days of the law's enactment. This bill requires manufacturers of electric wheelchairs and robotic walking devices to sell repair parts, software, manuals, and tools to independent repair shops and owners on fair terms, with notices to customers, facing FTC penalties for violations.
Where it stands
HR 5039 is in the committee stage, having been referred on August 26, 2025, to the Committee on Energy and Commerce and the Committee on the Judiciary. This multiple referral requires both committees to consider provisions within their jurisdictions, with each chair acting as a gatekeeper for further action.
HR 4475 US House Last action
July 17, 2025 BurdenLong shot

Medicare Orthotics and Prosthetics Patient-Centered Care Act

Glenn Thompson (Republican) · Sponsor of record · Official record ↗

What it does
The bill prohibits Medicare payments for orthotics and prosthetics delivered via drop shipment to patients who have not received fitting instruction from a qualified practitioner. It also expands the list of healthcare providers exempt from competitive acquisition programs to include physical therapists, occupational therapists, orthotists, and prosthetists, while clarifying Medicare coverage for the replacement of custom-fitted and custom-fabricated orthotic devices. This bill bars Medicare payment for orthotics and prosthetics shipped directly to patients without fitting instructions from a qualified practitioner, while clarifying coverage for custom-fitted replacements, hitting device makers and suppliers.
Where it stands
HR4475 was referred on July 17, 2025 to the House Committee on Energy and Commerce and the House Committee on Ways and Means. Both committees act as gatekeepers, as the source does not establish a primary panel.
HR 4441 US House Last action
July 16, 2025 BenefitLong shot

Patient Access to Innovative New Technologies Act of 2025

Mike Carey (Republican) · Sponsor of record · Official record ↗

What it does
This bill allows certain medical devices designated for expedited review to receive conditional Medicare add-on payments if they receive final regulatory approval before July 1 of the fiscal year. The provision applies to devices approved on or after July 1, 2023, and must be implemented in a budget-neutral manner. This bill lets breakthrough device manufacturers qualify for conditional Medicare new technology add-on payments even before their devices receive full approval, giving them Medicare reimbursement revenue earlier.
Where it stands
HR4441 is stalled in the House following its July 16, 2025 referral to the Committee on Ways and Means and the Committee on Energy and Commerce. Each committee chair serves as a gatekeeper for their respective jurisdictional provisions, with no upcoming meetings currently scheduled.
HR 3996 US House Last action
June 12, 2025 BurdenLong shot

Medicare Transaction Fraud Prevention Act

David Schweikert (Republican) · Sponsor of record · Official record ↗

What it does
This proposal would establish a two-year Medicare pilot program that uses a predictive risk-scoring algorithm to review claims for durable medical equipment and clinical diagnostic laboratory tests. The program applies only to beneficiaries who voluntarily opt in, and it allows the government to suspend high-risk transactions pending human review and beneficiary confirmation. This bill requires Medicare suppliers of durable medical equipment to have claims screened by a risk-scoring pilot, and high-risk transactions can be suspended pending review, delaying payment and adding documentation burdens.
Where it stands
The bill is stalled following its referral to the House Committee on Energy and Commerce and the House Committee on Ways and Means on June 12, 2025. No upcoming meetings are scheduled, and the multiple referral requires action by the chairs of both committees to advance.
S 2066 US Senate Last action
June 12, 2025 BurdenLong shot

Medicare Transaction Fraud Prevention Act

Tim Sheehy (Republican) · Sponsor of record · Official record ↗

What it does
This bill would establish a two-year Medicare pilot program that uses predictive algorithms to flag high-risk claims for durable medical equipment and laboratory tests. The program would require human review and beneficiary confirmation before suspending payments for transactions identified as risky by the software. This bill subjects Medicare suppliers of durable medical equipment to a pilot program where predictive algorithms can flag their claims as high-risk, suspending payments until human review and beneficiary confirmation, slowing cash flow and adding administrative work.
Where it stands
S2066 was read twice and referred to the Senate Committee on Finance on June 12, 2025, and remains stalled at this stage with no hearings or markups scheduled. The bill is currently inactive in committee, consistent with the common outcome where referred bills receive no action.
HR 3288 US House Last action
May 8, 2025 MixedLong shot

Access to Prescription Digital Therapeutics Act of 2025

Kevin Hern (Republican) · Sponsor of record · Official record ↗

What it does
The bill would require Medicare to cover prescription digital therapeutics and direct the government to establish payment codes and rates for these software-based medical devices. It also mandates that manufacturers report their private sector pricing and usage data to federal officials to inform the new payment system. This bill requires manufacturers of FDA-cleared prescription digital therapeutics to report private pricing and usage data to Medicare annually, with fines up to $10,000 per day, while granting them new Medicare and Medicaid payment coverage for their software devices.
Where it stands
HR3288 was referred on May 8, 2025, to the Committee on Energy and Commerce and the Committee on Ways and Means for consideration of provisions within their respective jurisdictions. The bill is currently stalled, as no hearings or markups have been scheduled by either committee chair.
S 1702 US Senate Last action
May 8, 2025 BurdenLong shot

Access to Prescription Digital Therapeutics Act of 2025

Shelley Moore Capito (Republican) · Sponsor of record · Official record ↗

What it does
This proposal would require Medicare to cover and pay for prescription digital therapeutics, which are software-based medical devices, starting in 2026. It would also mandate that manufacturers of these products report pricing and usage data to the government and establish a new Medicaid coverage category for such therapies. This bill requires manufacturers of FDA-cleared prescription digital therapeutics, which are software-based medical devices, to report annual pricing and usage data to the government with penalties up to $10,000 per day, while granting them new Medicare and Medicaid coverage and payment.
Where it stands
S. 1702 is stalled in the Senate Committee on Finance following its May 8, 2025, referral, with no scheduled meetings indicated in the record.
HR 3042 US House Last action
April 28, 2025 BenefitLong shot

MMEDS Act of 2025

Nicole Malliotakis (Republican) · Sponsor of record · Official record ↗

What it does
The legislation provides tax credits of 40 to 60 percent for medical manufacturers who operate in economically distressed zones or purchase goods and services from those areas. It also directs federal agencies to prioritize the development and distribution of health products for vulnerable populations facing combined health threats during pandemics. This bill gives medical device and supply manufacturers tax credits covering 40 to 60 percent of wages, benefits, and property in economically distressed zones or when sourcing from them, plus priority for pandemic products serving vulnerable populations, while plants outside those zones gain nothing.
Where it stands
The MMEDS Act of 2025 was referred on April 28, 2025, to the Committee on Ways and Means and the Committee on Energy and Commerce for consideration of provisions within their respective jurisdictions. No hearings, markups, or scheduled meetings have occurred since this referral, leaving the measure in a stalled posture at the committee stage.
HR 2372 US House Last action
March 26, 2025 BurdenLong shot

DEVICE Act of 2025

Ted Lieu (Democrat) · Sponsor of record · Official record ↗

What it does
The bill requires medical device manufacturers to notify the Food and Drug Administration before changing a device's design or reprocessing instructions, and within five days of widely disseminating safety-related communications to foreign health care providers. It also mandates that rapid assessment tests for reprocessing reusable devices receive FDA clearance only if accompanied by validated instructions and supporting data. This bill directly burdens medical device manufacturers by requiring written FDA notice before changing a device's design or reprocessing instructions, reporting foreign safety communications within five days, and providing validation data to obtain clearance for rapid assessment tests.
Where it stands
HR2372 was referred to the House Committee on Energy and Commerce on March 26, 2025, and remains in committee with no scheduled hearings or markups. The related measure HR1090 was referred to the Subcommittee on Health on February 24, 2023, and has not been reported or passed by a chamber.
S 983 US Senate Last action
March 12, 2025 BenefitLong shot

Hearing Device Coverage Clarification Act

Amy Klobuchar (Democrat) · Sponsor of record · Official record ↗

What it does
This act directs the Centers for Medicare & Medicaid Services to clarify within 60 days of enactment that implanted active middle ear hearing devices are classified as prosthetics. This classification ensures these devices are not subject to the existing Medicare exclusion for hearing aid coverage. This bill requires CMS to classify implanted active middle ear hearing devices as prosthetics, exempting them from Medicare's hearing aid exclusion so manufacturers of these implants gain coverage and increased demand.
Where it stands
S983 is referred to the Senate Committee on Finance with no scheduled meetings, a posture where the chair controls whether to schedule a markup or allow the bill to die quietly.
HR 1931 US House Last action
March 6, 2025 BenefitLong shot

Access to Pediatric Technologies Act of 2025

John Joyce (Republican) · Sponsor of record · Official record ↗

What it does
The bill requires the Secretary of Health and Human Services to establish national relative value units for qualifying pediatric medical devices upon manufacturer request, provided such units do not already exist. Manufacturers must submit verification and pricing data to the Secretary, who incorporates the new rates into the annual physician fee schedule rulemaking. This bill lets manufacturers of qualifying pediatric medical devices ask the Secretary of Health and Human Services to set Medicare payment rates, giving those businesses a formal path to get their products reimbursed.
Where it stands
HR1931 was referred on March 6, 2025 to the Committee on Energy and Commerce and the Committee on Ways and Means for periods to be subsequently determined by the Speaker. The bill remains at the initial committee stage with both chairs controlling whether a hearing or markup is scheduled.
HR 1632 US House Last action
February 26, 2025 MixedLong shot

Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

Chip Roy (Republican) · Sponsor of record · Official record ↗

What it does
This bill allows the FDA to grant marketing approval for drugs, biological products, and medical devices that are already legally sold in certain foreign countries or the United Kingdom, provided a public health need exists in the United States. The FDA must decide on these requests within 30 days, though Congress retains the power to override a denial through a joint resolution. This bill lets medical device makers win FDA approval for devices already sold in approved foreign countries, with a 30-day decision deadline, cutting the usual review time and cost to reach the US market, subject to user fees.
Where it stands
HR 1632 is stalled in the House Committee on Energy and Commerce and the House Committee Rules following referral to both panels on February 26, 2025. No hearings or markups have been scheduled for the measure.
HR 1539 US House Last action
February 24, 2025 BenefitLong shot

Medical Device Electronic Labeling Act

Jay Obernolte (Republican) · Sponsor of record · Official record ↗

What it does
The bill allows manufacturers to provide required medical device labeling solely through electronic means if the information is readily accessible and paper copies are provided free of charge upon request. The FDA Secretary may issue orders requiring specific information on physical labels if necessary to ensure device safety and effectiveness. This bill lets medical device and supply manufacturers provide required labeling, including for in vitro diagnostic devices, solely electronically, cutting printing costs, as long as paper copies are provided free on request and safety-critical physical labels can still be required.
Where it stands
HR1539 was referred to the House Committee on Energy and Commerce on February 24, 2025, where it currently awaits action from the committee chair. The related Senate companion S4519 is also stalled in committee, having been referred on May 13, 2026.
HR 1108 US House Last action
February 7, 2025 BenefitLong shot

Diagnostics Testing Preparedness Plan Act of 2025

Mariannette Miller-Meeks (Republican) · Sponsor of record · Official record ↗

What it does
This act would require the Secretary of Health and Human Services to develop and publish a plan for the rapid development, validation, manufacture, and distribution of diagnostic tests during public health emergencies. The Secretary would also be authorized to contract with public and private entities to increase domestic testing capacity for immediate response activities. This bill lets the Health and Human Services Secretary contract with diagnostic test manufacturers and distributors to expand domestic testing capacity, opening new federal contract opportunities and faster pathways for point-of-care and at-home tests during public health emergencies.
Where it stands
HR 1108 was referred to the House Committee on Energy and Commerce on February 7, 2025 and remains in the committee stage. The chair of this committee controls whether a markup or hearing is scheduled.
S 249 US Senate Last action
January 24, 2025 BenefitLong shot

Access to Pediatric Technologies Act of 2025

Marsha Blackburn (Republican) · Sponsor of record · Official record ↗

What it does
This proposal would require the Secretary of Health and Human Services to establish national payment rates for specific pediatric medical technologies upon request by their manufacturers. The bill sets a timeline where requests received by May 1 must be addressed in that year's rulemaking, while later requests are processed the following year. This bill lets medical device manufacturers of qualifying pediatric technologies request that HHS establish national Medicare payment rates, with requests received by May 1 handled that year, giving their pediatric devices a faster path to payment and market access.
Where it stands
S249 was read twice and referred to the Senate Committee on Finance on January 24, 2025, where it remains without a scheduled markup or hearing.
HR 675 US House Last action
January 23, 2025 MixedLong shot

Domestic SUPPLY Act of 2025

H. Morgan Griffith (Republican) · Sponsor of record · Official record ↗

What it does
This act establishes a federal partnership program with domestic manufacturers to guarantee the supply of personal protective equipment for public health emergencies and prohibits federal, state, and local agencies from using federal funds to purchase infectious disease prevention gear made outside the United States. This bill gives domestic manufacturers of personal protective equipment guaranteed federal purchasing partnerships if they meet quality, pricing, and US production requirements, and bars agencies from buying foreign-made PPE with federal funds.
Where it stands
HR675 was referred on January 23, 2025 to the Committee on Energy and Commerce and the Committee on Oversight and Government Reform, with no primary committee designated by the source. The bill is currently stalled in committee, where the chairs of both panels control whether any further action, such as a hearing or markup, occurs.
S 3213 US Senate Last action
November 19, 2025 BurdenLong shot

Destruction of Hazardous Imports Act

Rick Scott (Republican) · Sponsor of record · Official record ↗

What it does
This bill expands the authority of the Secretary of Health and Human Services to destroy any refused import, not just drugs and devices, if the item poses a significant public health risk. It also makes it a federal crime to move or sell these designated items into commerce. This bill lets the HHS Secretary destroy any refused import that poses a significant public health risk, so medical device and supply manufacturers whose imports are refused could lose their products instead of re-exporting them, and selling them becomes a federal crime.
Where it stands
S. 3213 was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on November 19, 2025. The bill is currently stalled in committee with no scheduled hearings or markups.
HR 10650 US House Last action
October 1, 2026 MixedLong shot

American Glove Act of 2026

Mike Carey (Republican) · Sponsor of record · Official record ↗

What it does
The bill would require federal agencies buying non-surgical nitrile gloves through the AbilityOne Program or other shared purchasing arrangements to get those gloves only from US-based, US-majority-owned manufacturers that are free of foreign control or influence and can produce at commercial scale, with each arrangement backed by a supplier agreement of at least two years that includes binding minimum purchase commitments. Agencies would have to certify compliance and could not let intermediaries such as nonprofit agencies, distributors, or prime vendors satisfy the rules unless an actual qualified domestic manufacturer holds the manufacturing agreement, while allowing existing vehicles to be modified rather than terminated. This bill requires federal agencies buying nitrile gloves to purchase only from majority US-owned domestic manufacturers through multi-year supplier agreements, while barring foreign-owned glove makers and relabeling distributors from those federal sales.
Where it stands
HR 10650, the American Glove Act of 2026, was referred to the House Committee on Oversight and Government Reform on October 1, 2026. Referral places the bill in committee, where the committee chair decides whether the bill ever gets a hearing or a markup.

May also reach

Measures that reach Medical Devices & Supplies indirectly

Through a product these businesses make, a customer they serve, a competitor, or a study about them. Read these as possibilities, not duties.

HR 1703 US House Last action
October 14, 2026 May reachGood chance of law

Choices for Increased Mobility Act of 2026

John Joyce (Republican) · Sponsor of record · Official record ↗

What it does
The bill would require Medicare, starting January 1, 2028, to create separate billing codes for ultralightweight manual wheelchairs based on whether the frame base uses titanium or carbon fiber, and to pay suppliers for titanium or carbon fiber chairs at the normal Medicare payment rate. It would also let suppliers charge Medicare beneficiaries the difference between the supplier's actual charge and the Medicare payment for those chairs, with a possible advance notice of that financial liability. This bill requires Medicare to create separate billing codes for ultralightweight manual wheelchairs based on titanium or carbon fiber frames, letting wheelchair manufacturers bill standard rates while beneficiaries pay the cost difference.
Where it stands
The bill has cleared both chambers: the House passed it under suspension of the rules on July 20, 2026, and the Senate passed the House text without amendment on September 30, 2026, so both chambers have agreed to identical text. It is no longer pending in either chamber; what remains is enrollment, signature by the Speaker and the Senate's presiding officer, and presentment to the President, none of which the record shows has happened yet.
S 247 US Senate Last action
January 24, 2025 May reachGood chance of law

Choices for Increased Mobility Act of 2025

Marsha Blackburn (Republican) · Sponsor of record · Official record ↗

What it does
The bill would direct Medicare, starting January 1, 2026, to create separate billing codes for ultralightweight manual wheelchairs depending on whether the frame base is made with titanium or carbon fiber. It would let suppliers keep receiving Medicare's standard payment for such wheelchairs and additionally charge the patient the gap between that payment and the supplier's actual charge, with a possible advance notice requirement so beneficiaries know they may owe money. This bill requires Medicare to create separate billing codes for ultralight wheelchairs with titanium or carbon fiber frames and lets suppliers bill Medicare while charging patients the difference, benefiting wheelchair manufacturers and suppliers.
Where it stands
S247 was read twice and referred to the Senate Committee on Finance on January 24, 2025, and no further action or meetings are scheduled. The bill now sits at the chamber's most common choke point, where the Finance chair decides whether anything happens at all and committees need not act on referred bills.
HR 6214 US House Last action
November 20, 2025 May reachLong shot

Kidney Care Access Protection Act

Carol D. Miller (Republican) · Sponsor of record · Official record ↗

What it does
Starting in 2026, the bill would extend Medicare's extra transitional payments for new kidney dialysis drugs and devices to at least 3 years each, add a permanent payment adjustment worth 65 percent of a calculated amount once that transitional period ends, and let breakthrough-designated dialysis devices and capital-related device assets qualify for transitional equipment payments. It would also require Medicare Advantage plans' payments to support these new products through direct adjustments to providers of services and dialysis facilities, add a forecast error correction to the annual dialysis payment update, add chronic kidney disease screening to the Medicare annual wellness visit, and expand the kidney disease education benefit to stage V patients, allow physician assistants, nurse practitioners, and clinical nurse specialists to furnish it, let dialysis facilities provide it, and pay those facilities for it separately from the bundled dialysis rate. This bill gives manufacturers of new kidney dialysis drugs and devices at least 3 years of extra Medicare transitional add-on payments, a permanent 65 percent payment adjustment afterward, and equipment payment eligibility for breakthrough-designated dialysis devices.
Where it stands
HR 6214 was referred on November 20, 2025 to the House Committee on Ways and Means and, in addition, to the House Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, with neither committee established as the primary panel. The House Committee on Energy and Commerce held a hearing on the bill on September 15, 2026, but no markup has been scheduled and no upcoming meetings appear in the calendar data.
HR 2902 US House Last action
April 10, 2025 May reachLong shot

SOAR Act of 2025

David G. Valadao (Republican) · Sponsor of record · Official record ↗

What it does
This bill removes oxygen and related equipment from the Medicare competitive bidding program and establishes new payment rates for these services starting in 2026. It also adds reimbursement for respiratory therapist services and mandates electronic templates for prescribing practitioners to document medical necessity. This bill requires Medicare to set higher payment rates that account for the cost of liquid oxygen equipment and infrastructure, benefiting device and medical supply manufacturers with better reimbursement when their products reach patients.
Where it stands
HR2902 is stalled in committee after a January 8, 2026 hearing by the House Committee on Energy and Commerce, following its April 10, 2025 referral to that panel and the Committee on Ways and Means. The source does not designate a primary committee, so both chairs act as gatekeepers for further action.
S 1406 US Senate Last action
April 10, 2025 May reachLong shot

SOAR Act of 2025

Bill Cassidy (Republican) · Sponsor of record · Official record ↗

What it does
This act would remove home oxygen equipment and related services from Medicare's competitive bidding program and establish new fee schedules for these items starting in 2026. It also would mandate specific service standards for suppliers, create reimbursement pathways for respiratory therapists, and implement electronic templates to verify medical necessity. This bill removes home oxygen equipment from Medicare competitive bidding and sets new fee schedules starting in 2026, giving manufacturers and suppliers of oxygen devices guaranteed payment rates and requiring compliance with service standards and electronic verification templates.
Where it stands
The SOAR Act of 2025 was read twice and referred to the Senate Committee on Finance on April 10, 2025. It is currently stalled in committee with no scheduled hearings or markups.
HR 1921 US House Last action
March 6, 2025 May reachLong shot

Hearing Device Coverage Clarification Act

Michelle Fischbach (Republican) · Sponsor of record · Official record ↗

What it does
This proposal would direct the Centers for Medicare & Medicaid Services to clarify within 60 days of enactment that fully implanted active middle ear hearing devices are considered prosthetics. This classification exempts these specific devices from the Medicare hearing aid coverage exclusion. This bill directs CMS to classify fully implanted active middle ear hearing devices as prosthetics, exempting them from the Medicare hearing aid exclusion so manufacturers and implanting clinics gain Medicare payment eligibility and more sales.
Where it stands
HR 1921 is stalled in a multiple referral to the House Committee on Energy and Commerce and the House Committee on Ways and Means as of March 6, 2025, with no primary committee designated in the record. Both committee chairs act as gatekeepers for potential hearings or markups, though the source does not indicate which panel holds primary jurisdiction.
HR 193 US House Last action
January 3, 2025 May reachLong shot

Maintaining Innovation and Safe Technologies Act

David Schweikert (Republican) · Sponsor of record · Official record ↗

What it does
The Secretary of Health and Human Services must issue guidance by January 1, 2027, detailing payment requirements for Medicare Part B coverage of remote monitoring devices that use artificial intelligence. This guidance specifically targets devices like continuous glucose monitors that transmit data to health care providers for patient management. This bill requires HHS to issue Medicare Part B payment guidance for AI-enabled remote monitoring devices like continuous glucose monitors, creating clearer coverage eligibility for manufacturers of those medical supplies.
Where it stands
HR193 was referred on January 3, 2025, to the House Committee on Energy and Commerce and the House Committee on Ways and Means. The bill is currently in committee with no scheduled meetings, subject to consideration by each panel for provisions within their respective jurisdictions.
HR 10640 US House Last action
October 1, 2026 May reachLong shot

Urban Health Transformation Act of 2026

Maxine Waters (Democrat) · Sponsor of record · Official record ↗

What it does
This proposal would create an Urban Health Transformation Program run by the Centers for Medicare & Medicaid Services, appropriating $10 billion a year for fiscal years 2027 through 2031, a total of $50 billion, plus $200 million for fiscal year 2026 setup costs, to be divided among states with approved plans for improving urban health care. States would apply once by the end of 2026 with no matching funds required, and would spend their share on at least three activities such as provider payments, chronic disease prevention, health technology like remote monitoring and artificial intelligence, clinician recruitment, and substance use and mental health treatment, with unused money returned to the Treasury and funds cut off for states that spend against their approved plans. This bill funds state purchases of remote monitoring devices, robotics, and other advanced health technologies for urban hospitals and clinics, creating new demand for medical device manufacturers through $50 billion in federal grants.
Where it stands
HR10640 was referred on October 1, 2026 to the House Committee on Energy and Commerce and, in addition, to the House Committee on Ways and Means, with the period for each referral to be determined by the Speaker. The bill is at the earliest committee stage: no hearing or markup appears in the calendar data, and each committee's chair controls whether one is ever noticed.
S 5671 US Senate Last action
September 30, 2026 May reachLong shot

State Strategic Stockpile Act of 2026

Margaret Wood Hassan (Democrat) · Sponsor of record · Official record ↗

What it does
The bill would extend the federal pilot program supporting State medical stockpiles for several more years, authorizing such sums as may be necessary for each of fiscal years 2027 through 2031, and would require grant recipients to coordinate with health care entities, health officials, and emergency management officials and to share best practices with other States, including through possible regional stockpiling approaches. It would also direct a Government Accountability Office report on the impact of regional stockpiling approaches and would require the Public Health Emergency Medical Countermeasures Enterprise to consult State, local, Tribal, and territorial public health departments or officials by removing the current 'as appropriate' qualifier. This bill gives states federal funding through 2031 to build and maintain stockpiles of medical products, creating new demand for medical device and supply manufacturers whose equipment is purchased for those inventories.
Where it stands
S5671 was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on September 30, 2026. It now sits at the committee stage, which is the chamber's most common kill point, and no further action is scheduled in our calendar data.
S 5475 US Senate Last action
September 23, 2026 May reachLong shot

Timely Access to Coverage Decisions Act

Ben Ray Luján (Democrat) · Sponsor of record · Official record ↗

What it does
The bill would impose deadlines on the private contractors that make Medicare local coverage decisions, requiring them within 60 days to decide whether a formal request or reconsideration request is complete, to tell requesters what is missing if it is not, and to act on complete requests within 1 year, with a new option for interested parties such as beneficiaries, providers, and suppliers to have the Secretary review a reconsideration decision. The bill would also require contractors, before issuing new or substantively revised coverage determinations, to publish a draft with supporting evidence, hold public meetings with remote access and an expert panel, take public comment for at least 30 days, and delay the final determination's effective date by at least 45 days, all taking effect one year after enactment. This bill gives medical device and supply manufacturers faster, more predictable Medicare coverage decisions by imposing 60-day completeness and 1-year decision deadlines on contractors, though new public-comment steps could slow final coverage rules.
Where it stands
S5475, the Timely Access to Coverage Decisions Act, was read twice and referred to the Committee on Finance on September 23, 2026. The bill is at the committee stage, the chamber's most common kill point, and no markup has been scheduled.
S 5439 US Senate Last action
September 17, 2026 May reachLong shot

A bill to direct the Secretary of Agriculture to improve safety standards for wildland firefighters.

Adam B. Schiff (Democrat) · Sponsor of record · Official record ↗

What it does
The bill would direct the Agriculture Department, working with other federal agencies, to develop a strategy within one year to make respiratory protective equipment commercially available to wildland firefighters and support staff when wildfire smoke exposure exceeds existing federal smoke exposure limits, and to determine which equipment is appropriate. It would also have the department convene a task force to develop an interim smoke exposure standard, review and update safety and equipment standards for wildland firefighters, and incorporate the NFPA 1984 respirator standard by reference. This bill directs federal agencies to make respiratory protective equipment available to wildland firefighters, creating new procurement demand for manufacturers that meet the NFPA 1984 respirator standard.
Where it stands
S5439 was read twice and referred to the Senate Committee on Agriculture, Nutrition, and Forestry on September 17, 2026. The bill is at the committee stage, the chamber's most common kill point, and no calendar placement for this bill appears in the record.
HR 10333 US House Last action
September 10, 2026 May reachLong shot

AACCENT Act

Debbie Dingell (Democrat) · Sponsor of record · Official record ↗

What it does
The bill would have the Department of Health and Human Services award three 5-year competitive grants, totaling up to $9,000,000 per year, to create a network of National Resource Centers on Augmentative and Alternative Communication that provide training, technical assistance, data collection, and information to people with significant expressive communication disabilities and the educators, providers, employers, and agencies that serve them. It would authorize $9,000,000 in appropriations for each of fiscal years 2027 through 2031, cap administrative costs at 15 percent of grant funds, and require each funded center to be guided by an 11-person advisory council made up entirely of people with these disabilities. This bill indirectly benefits manufacturers of augmentative and alternative communication devices by funding centers that must increase access to and effective implementation of the full range of such devices for people with significant expressive communication disabilities.
Where it stands
HR10333 was referred to the House Committee on Education and Workforce on September 10, 2026 and sits at the start of the committee stage, with no hearing or markup noticed.

Subscribe

One of these bills names your business.

Subscribe under Medical Devices & Supplies and Tocsin carries your position on the measures you choose from this docket, files what the law requires, and reports monthly. Introductory for $249 a month. Standard for $499. No portal, no password; this docket is yours, and the reports arrive by email.

IntroductoryCorrespondence on 1 bill a month, monthly reports$249/mo StandardCorrespondence on 3 a month, in-person on 1 a quarter, quarterly letter and legislator list$499/mo PremiumCorrespondence on 5 a month, in-person on 3 a quarter, quarterly briefing call$999/mo Subscribe under Medical Devices & Supplies → Compare plans in detail →